Evidence map›Paper›PMID 42087049›Full record

ArticleMedScience2026

Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study.

Rongbei Liu, Tingting Wu, Jian Tang, Hongjie Zhang, Yanyun Fan, Haibo Sun, Chen Xie, Qunyan Zhou, Hongzhen Xu, Yabi Zhu and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rongbei Liu *Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. liurongbei@zju.edu.cn.
Tingting Wu *Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
Jian TangDepartment of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Hongjie ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Yanyun FanDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, China.
Haibo SunDepartment of Gastroenterology and Endoscopy Center, The First Hospital of Jilin University, Changchun, 130021, China.
Chen XieDepartment of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Qunyan ZhouDepartments of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, China.
Hongzhen XuDepartment of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, 610044, China.
Yabi ZhuDepartment of Gastroenterology, Lishui People's Hospital, Lishui, 323006, China.
Mei YeDepartment of Gastroenterology & Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, 430062, China.
Xiaomin ShiThe Affiliated Hospital of Southwest Medical University, Chongqing, 404100, China.
Feng Tian1st Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, 110072, China.
Haiyan ShenDepartment of Gastroenterology, The Second Hospital of Jiaxing, Jiaxing, 314099, China.
Dan XuDepartment of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.
Ying ZhouDepartment of Gastroenterology, Ningbo Medical Center Lihuili Hospital, Ningbo, 315046, China.
Qian CaoDepartment of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. Caoq@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infliximab (IFX) for inflammatory bowel disease (IBD) treatment may increase the risk of hepatitis B virus (HBV) reactivation, particularly in areas with high HBV prevalence such as China. This study aimed to evaluate HBV reactivation/infection, liver dysfunction, vaccination efficacy and strategies in IBD patients undergoing IFX therapy. This retrospective, multicenter study included 4183 IBD patients from 15 hospitals across China, who were divided into six groups according to the HBV status. Demographic features, HBV vaccination status, reactivation/infection rates, and liver dysfunction outcomes were collected, with data collection performed from 2009 to 2022. We found that HBV reactivation rate was notably higher in HBsAg positive group than other groups (P < 0.05) despite antiviral treatment. Although only 29% of patients were immunized at IFX initiation and almost no patients got vaccinated against HBV during IFX treatment, no patients experienced HBV infection in the susceptible population group. The study underscores a critical need for rigorous HBV screening before IFX initiation. Despite antiviral prophylaxis, the importance of continuous monitoring of HBV DNA is necessary for HBsAg positive patients. HBsAg negative patients, including the susceptible population, had a very low risk of new HBV infection, thus reassuring patients and physicians of the safety of IFX in this cohort.

Indexed as

Hepatitis BHepatitis B virusInflammatory Bowel DiseasesInfliximabVirus ActivationAdultChinaFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultInfliximabHBVIBDreactivationvaccination

Identifiers

PMID42087049

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.